Publications 2025

Aamodt AH, Ueland T, Boldingh M, Bezgal BE, Argren MB, Dunne CA, Otterdal K, Gregersen I, Bjerkeli V, Michelsen AE, Husøy A, Morsund ÅH, Devik K, Poole AC, Gjendemsjø KB, Schlüter K, Mathisen SM, Aalstad-Johansen M, Skattør TH, Sønnervik J, Boye TB, Popperud TH, Høgestøl EA, Harbo HF, Lund-Johansen F et al. (2025)
Altered amyloid plasma profile in patients with disabling headaches after SARS-CoV-2 infection and vaccination
BMJ Neurol Open, 7 (2), e001013
DOI 10.1136/bmjno-2024-001013, PubMed 40881041

Publications 2024

Gilhus NE, Andersen H, Andersen LK, Boldingh M, Laakso S, Leopoldsdottir MO, Madsen S, Piehl F, Popperud TH, Punga AR, Schirakow L, Vissing J (2024)
Generalized myasthenia gravis with acetylcholine receptor antibodies: A guidance for treatment
Eur J Neurol, 31 (5), e16229
DOI 10.1111/ene.16229, PubMed 38321574

Leone MA, Helbok R, Bianchi E, Yasuda CL, Konti M, Ramankulov D, Lolich M, Lovrencic-Huzjan A, Kovács T, Armon C, Cotelli MS, Cavallieri F, Grosu O, Kiteva-Trenchevska G, Rodriguez-Leyva I, Boldingh M, Brola W, Maia LF, de Seabra MML, Davidescu EI, Popescu BO, Kopishinskaia S, Bassetti CLA, Moro E, ENERGY Study Group (§) (2024)
Outcome predictors of post-COVID conditions in the European Academy of Neurology COVID-19 registry
J Neurol, 271 (6), 3153-3168
DOI 10.1007/s00415-024-12212-8, PubMed 38436682

Publications 2012

Maniaol AH, Boldingh M, Brunborg C, Harbo HF, Tallaksen CME (2012)
Smoking and socio-economic status may affect myasthenia gravis
Eur J Neurol, 20 (3), 453-460
DOI 10.1111/j.1468-1331.2012.03843.x, PubMed 22934661